Vaxcyte Achieves Major Milestone: OPUS-1 and OPUS-2 Phase 3 Trials for VAX-31 Fully Enrolled, Setting Stage for New Vaccine Standard
Market Chameleon (Mon, 23-Mar 9:33 AM)
Vaxcyte’s $550 Million Public Offering Highlights Expanding Vaccine Ambitions
Market Chameleon (Fri, 30-Jan 8:50 AM)
